Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

Akeso, Inc. (9926.HK)  (Akeso or the Company) announced today that its proprietary first-in-class trispecific antibody, AK150 ...